A Phase I, Single-Sequence, Open-Label, Single- and Multiple-Dose Study of the Effect of Evobrutinib on Midazolam Pharmacokinetics in Healthy Participants
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Evobrutinib (Primary) ; Midazolam
- Indications Encephalomyelitis; Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Merck KGaA
- 22 Mar 2021 Status changed from recruiting to completed.
- 19 Jan 2021 Planned number of patients changed from 16 to 18.
- 19 Jan 2021 Status changed from not yet recruiting to recruiting.